First Patient Dosed in Alpibectir-Ethionamide TB Trial

BioVersys AG, in collaboration with GSK, has dosed the first patient in a 14-day Phase 2 clinical trial for alpibectir-ethionamide (AlpE) combined with first-line tuberculosis (TB) drugs. This trial, part of the UNITE4TB project, aims to evaluate the early bactericidal activity and safety of AlpE in 60 patients with pulmonary TB. Supported by the European Union, the trial reflects a significant step in combating drug-resistant TB.

The collaboration aims to advance AlpE in TB treatment, with BioVersys focusing on TB meningitis trials. The trial seeks insights into AlpE's potential to enhance current TB treatments and is expected to yield topline data by Q2 2026, potentially addressing the high unmet need in TB therapies, particularly in drug-resistant cases.